FDA Grants Fast Track Designation to Pasithea's PAS-004 for Neurofibromatosis Type 1 Treatment
KTTA has more than doubled off its 52-week low of $0.281.
Summary
Pasithea Therapeutics announced that the FDA has granted Fast Track designation to its drug candidate, PAS-004, for the treatment of Neurofibromatosis Type 1 (NF1) associated Plexiform Neurofibromas (PN). This positive regulatory milestone follows a recent news report of significant net and operating losses for the company. Fast Track designation is crucial for a clinical-stage biotech like Pasithea, as it facilitates expedited development and review, including more frequent FDA interactions and potential eligibility for accelerated approval or priority review. This development significantly de-risks the drug's path to market and is a material positive catalyst for the company, especially given its small market capitalization. Investors will now watch for updates on the ongoing Phase 1/1b clinical trial for PAS-004.
At the time of this announcement, KTTA was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.1M. The 52-week trading range was $0.28 to $3.79. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.